- Home
- XNCR vs ARVN Comparison
XNCR vs ARVN Comparison
Compare XNCR & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XNCR
- ARVN
- Stock Information
- Founded
- XNCR 1997
- ARVN 2015
- Country
- XNCR United States
- ARVN United States
- Employees
- XNCR N/A
- ARVN N/A
- Industry
- XNCR Biotechnology: Pharmaceutical Preparations
- ARVN Biotechnology: Pharmaceutical Preparations
- Sector
- XNCR Health Care
- ARVN Health Care
- Exchange
- XNCR Nasdaq
- ARVN Nasdaq
- Market Cap
- XNCR 547.8M
- ARVN 456.2M
- IPO Year
- XNCR 2013
- ARVN 2018
- Fundamental
- Price
- XNCR $8.62
- ARVN $7.62
- Analyst Decision
- XNCR Buy
- ARVN Buy
- Analyst Count
- XNCR 10
- ARVN 22
- Target Price
- XNCR $23.33
- ARVN $20.21
- AVG Volume (30 Days)
- XNCR 726.1K
- ARVN 1.4M
- Earning Date
- XNCR 11-05-2025
- ARVN 10-29-2025
- Dividend Yield
- XNCR N/A
- ARVN N/A
- EPS Growth
- XNCR N/A
- ARVN N/A
- EPS
- XNCR N/A
- ARVN N/A
- Revenue
- XNCR $146,929,000.00
- ARVN $372,800,000.00
- Revenue This Year
- XNCR $22.06
- ARVN $4.87
- Revenue Next Year
- XNCR N/A
- ARVN N/A
- P/E Ratio
- XNCR N/A
- ARVN N/A
- Revenue Growth
- XNCR N/A
- ARVN 299.57
- 52 Week Low
- XNCR $6.92
- ARVN $5.90
- 52 Week High
- XNCR $27.24
- ARVN $29.61
- Technical
- Relative Strength Index (RSI)
- XNCR 55.91
- ARVN 50.66
- Support Level
- XNCR $8.25
- ARVN $7.58
- Resistance Level
- XNCR $8.73
- ARVN $8.23
- Average True Range (ATR)
- XNCR 0.37
- ARVN 0.38
- MACD
- XNCR 0.06
- ARVN 0.01
- Stochastic Oscillator
- XNCR 69.03
- ARVN 35.11
About XNCR Xencor Inc.
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.
About ARVN Arvinas Inc.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.